Cited by 6,470Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation

Open access

The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators·2001·New England Journal of Medicine

DOI 10.1056/nejmoa010746

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Despite current treatments, patients who have acute coronary syndromes without ST-segment elevation have high rates of major vascular events. We evaluated the efficacy and safety of the antiplatelet agent clopidogrel when given with aspirin in such patients. METHODS: We randomly assigned 12,562 patients who had presented within 24 hours after the onset of symptoms to receive clopidogrel (300 mg immediately, followed by 75 mg once daily) (6259 patients) or placebo (6303 patients) in addition to aspirin for 3 to 12 months. RESULTS: The first primary outcome--a composite of death from cardiovascular causes, nonfatal myocardial infarction, or stroke--occurred in 9.3 percent of the patients in the clopidogrel group and 11.4 percent of the patients in the placebo group (relative risk with clopidogrel as compared with placebo, 0.80; 95 percent confidence interval, 0.72 to 0.90; P<0.001). The second primary outcome--the first primary outcome or refractory ischemia--occurred in 16.5 percent of the patients in the clopidogrel group and 18.8 percent of the patients in the placebo group (relative risk, 0.86; 95 percent confidence interval, 0.79 to 0.94; P<0.001). The percentages of patients with in-hospital refractory or severe ischemia, heart failure, and revascularization procedures were also significantly lower with clopidogrel. There were significantly more patients with major bleeding in the clopidogrel group than in the placebo group (3.7 percent vs. 2.7 percent; relative risk, 1.38; P=0.001), but there were not significantly more patients with episodes of life-threatening bleeding (2.2 percent [corrected] vs. 1.8 percent; P=0.13) or hemorrhagic strokes (0.1 percent vs. 0.1 percent). CONCLUSIONS: The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation. However, the risk of major bleeding is increased among patients treated with clopidogrel.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa010746

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Self-citation
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 4,204
Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes
The GUSTO-I Investigators (1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390704 · Cited by 1,431
Self-citation
Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction
The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators (1998) · New England Journal of Medicine · doi:10.1056/nejm199805213382102 · Cited by 1,330
Self-citation
Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
Rao, A. K., Pratt, C. M., Berke, A. D., Jaffe, A. S., Ockene, I. S., SCHREIBER, T. L., Bell, W. R., Knatterud, G. L., ROBERTSON, T. L., & Terrin, M. L. (1988) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(88)90158-1 · Cited by 979
Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial
Simoons, M. L. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05060-1 · Cited by 698
Low-molecular-weight heparin during instability in coronary artery disease
Fragmin during Instability in Coronary Artery Disease (FRISC) study group (1996) · The Lancet · doi:10.1016/s0140-6736(96)91270-2 · Cited by 683
Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
Wallentin, L. C., Swahn, E., Kontny, F. P., Husted, S., Lagerqvist, B., Ståhle, E., Jd, N., Dellborg, M., Geiran, O. R., Grande, P., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)07350-x · Cited by 405
Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists
Chew, D. P., Bhatt, D. L., Sapp, S. K., & Topol, E. J. (2001) · Circulation · doi:10.1161/01.cir.103.2.201 · Cited by 359

Flagged first, then by citations

Show all 16 references

Sorted by citations

Items 601–700 of 1,007

Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization
Mobley, J. E., Bresee, S. J., Wortham, D. C., Craft, R. M., Snider, C. C., & Carroll, R. C. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.10.042 · Cited by 129
Twelve Versus Six Months of Clopidogrel to Reduce Major Cardiac Events in Patients Undergoing γ-Radiation Therapy for In-Stent Restenosis
Waksman, R., Ajani, A. E., Pinnow, E. E., Cheneau, E. F., Leborgne, L., Dieble, R., Bui, A. B., Satler, L. F., Pichard, A. D., Kent, K. K., et al. (2002) · Circulation · doi:10.1161/01.cir.0000028605.04359.fe · Cited by 129
Meta-Analysis of the Efficacy and Safety of Clopidogrel Plus Aspirin as Compared to Antiplatelet Monotherapy for the Prevention of Vascular Events
Bowry, A., Brookhart, M. A., & Choudhry, N. K. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.11.057 · Cited by 128
A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans
Jakubowski, J. A., Matsushima, N., Asai, F., Naganuma, H., Brandt, J. T., Hirota, T., Freestone, S., & Winters, K. J. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02792.x · Cited by 128
Incidence, Timing, and Correlates of Stent Thrombosis With the Polymeric Paclitaxel Drug-Eluting Stent
Ellis, S. G., Colombo, A., Grube, E., Popma, J. J., Koglin, J., Dawkins, K. D., & Stone, G. W. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.015 · Cited by 128
Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis
COMBESCURE, C., Fontana, P., Mallouk, N., Berdagué, P., Labruyère, C., Barazer, I., Gris, J., Laporte, S., Fabbro-Péray, P., & Reny, J. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03809.x · Cited by 127
C-Terminal Provasopressin (Copeptin) is Associated With Left Ventricular Dysfunction, Remodeling, and Clinical Heart Failure in Survivors of Myocardial Infarction
Kelly, D., Squire, I. B., Khan, S. Q., Quinn, P. A., Struck, J., Morgenthaler, N. G., Davies, J. E., & Ng, L. L. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.07.231 · Cited by 131
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes
Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., & Stevenson, W. G. (2006) · Circulation · doi:10.1161/circulationaha.106.655761 · Cited by 130
Renal function and outcomes in acute coronary syndrome: impact of clopidogrel
Keltai, M., Tonelli, M. A., Mann, J. F. E., Sitkei, E., Lewis, B. S., Hawken, S., Mehta, S. R., Yusuf, S., & for the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial investigators (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000220582.19516.a6 · Cited by 126
Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome.
Cuisset, T., Cayla, G., Frère, C., Quilici, J., Poyet, R., Gaborit, B., Bali, L., Morange, P., Alessi, M., & Bonnet, J.-L. (2009) · EuroIntervention · doi:10.4244/51 · Cited by 126
ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery,⁎Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease)
Hirsch, A. T., Haskal, Z. J., HERTZER, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., Hiratzka, L. F., Murphy, W. R. C., Olin, J. W., Puschett, J. B., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.02.024 · Cited by 129
Secretory Phospholipase A2-IIA and Cardiovascular Disease
Holmes, M. V., Simon, T., Exeter, H. J., Folkersen, L., Asselbergs, F. W., Guardiola, M., Cooper, J. A., Palmen, J., Hubacek, J. A., Carruthers, K. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.06.044 · Cited by 120
Interaction Between Cigarette Smoking and Clinical Benefit of Clopidogrel
Desai, N. R., Mega, J. L., Jiang, S., Cannon, C. P., & Sabatine, M. S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.044 · Cited by 125
Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients
Muhlestein, J. B. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0177 · Cited by 125
Management of Antithrombotic Therapy after Acute Coronary Syndromes
Rodríguez, F., & Harrington, R. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1607714 · Cited by 133
Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation
Main, C., Palmer, S. C., Griffin, S. C., Jones, L., Orton, V., Sculpher, M. J., Henderson, R., Sudlow, C. L. M., Hawkins, N., & Riemsma, R. P. (2004) · Health Technology Assessment · doi:10.3310/hta8400 · Cited by 125
Acute coronary syndrome without ST elevation: implementation of new guidelines
Hamm, C. W., Bertrand, M. E., & D, E. B. M. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06585-0 · Cited by 125
Magnetically Targeted Endothelial Cell Localization in Stented Vessels
Pislaru, S. V., Harbuzariu, A., Gulati, R., Witt, T. A., Sandhu, N. P., Simari, R. D., & Sandhu, G. S. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.069 · Cited by 124
Part 9: Acute Coronary Syndromes
O’Connor, R. E., Ali, A. S., Brady, W. J., Ghaemmaghami, C. A., Menon, V., Welsford, M., & Shuster, M. (2015) · Circulation · doi:10.1161/cir.0000000000000263 · Cited by 128
Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021
Nicolau, J. C., Feitosa, G. S., Petriz, J. L. F., Furtado, R. H. D. M., Précoma, D. B., Lemke, W., Lópes, R. D., Timerman, A., Marin‐Neto, J. A., Bezerra, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210180 · Cited by 162
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER) trial: study design and rationale
Committees, T. T. C. E. A. S. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.07.001 · Cited by 124
Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention
Beinart, S. C., Kolm, P., Veledar, E., Zhang, Z., Mahoney, E. M., Bouin, O., Gabriel, S., Jackson, J., Chen, R. K., Jaime, J., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.03.073 · Cited by 123
The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes
Angiolillo, D. J. (2012) · Drugs · doi:10.2165/11640880-000000000-00000 · Cited by 123
Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents
Natarajan, A., Zaman, A., & Marshall, S. M. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.023 · Cited by 119
Half-Dose Direct Oral Anticoagulation Versus Standard Antithrombotic Therapy After Left Atrial Appendage Occlusion
Rocca, D. G. D., Magnocavallo, M., Biase, L. D., Mohanty, S., Trivedi, C. G., Tarantino, N. M., Gianni, C., Lavalle, C., Niekerk, C. J. V., Romero, J. E., et al. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.07.031 · Cited by 122
Clopidogrel for the secondary prevention of stroke
Diener, H., Ringleb, P. A., & Savi, P. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.5.755 · Cited by 122
Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet action
Payne, D. A., Hayes, P. D., Jones, C. I., Belham, P., Naylor, A. R., & Goodall, A. H. (2002) · Journal of Vascular Surgery · doi:10.1067/mva.2002.122027 · Cited by 122
Stabilization of atherosclerotic plaques: an update
Ylä‐Herttuala, S., Bentzon, J. F., Daemen, M. J. A. P., Falk, E., García‐García, H. M., Herrmann, J., Hoefer, I. E., Jauhiainen, S., Jukema, J. W., Krams, R., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht301 · Cited by 127
High incidence of clopidogrel‐associated gastrointestinal bleeding in patients with previous peptic ulcer disease
Ng, F. H., Wong, S., Chang, C. M., Chen, W. H., Kng, C., Lanas, A. I., & Wong, B. C. Y. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01693.x · Cited by 121
Clopidogrel Response Variability and Future Therapies
O’Donoghue, M. L., & Wiviott, S. D. (2006) · Circulation · doi:10.1161/circulationaha.106.643171 · Cited by 121
Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?
Nguyen, M. C., Lim, Y. L., Walton, A., Lefkovits, J., Agnelli, G., Goodman, S. G., Budaj, A., Gulba, D. C., Allegrone, J., Brieger, D. B., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm186 · Cited by 121
Clopidogrel response variability: Current status and future directions
Ferreiro, J. L., & Angiolillo, D. J. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0185 · Cited by 120
Veterans Affairs/Department of Defense Clinical Practice Guideline for the Management of Adult Stroke Rehabilitation Care
Bates, B. E., Choi, J. Y., Duncan, P. W., Glasberg, J. J., Graham, G. D., Katz, R. C., Lamberty, K. J., Reker, D. M., & Zorowitz, R. D. (2005) · Stroke · doi:10.1161/01.str.0000180432.73724.ad · Cited by 121
Twelve-Month Results of a Randomized Trial Comparing Mono With Dual Antiplatelet Therapy in Endovascularly Treated Patients With Peripheral Artery Disease
Strobl, F. F., Brechtel, K., Schmehl, J., Zeller, T., Reiser, M. F., Claussen, C. D., & Tepe, G. (2013) · Journal of Endovascular Therapy · doi:10.1583/13-4275mr.1 · Cited by 119
The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines
Bell, A., Roussin, A., Cartier, R., Chan, W., Douketis, J. D., Gupta, A. K., Kraw, M. E., Lindsay, T. F., Love, M. P., Pannu, N., et al. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.12.015 · Cited by 118
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Price, M., Walder, J. S., Baker, B. A., Heiselman, D., Jakubowski, J., Logan, D. K., Winters, K., Li, W., & Angiolillo, D. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.042 · Cited by 123
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study
Baber, U., Dangas, G., Cohen, D. J., Gibson, C. M., Mehta, S. R., Angiolillo, D. J., Pocock, S., Krucoff, M. W., Kastrati, A., Ohman, E. M., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.09.006 · Cited by 119
Guidelines for the management of acute coronary syndromes 2006
(2006) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00304.x · Cited by 118
Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: Physician practice in the CRUSADE registry
Wang, T. Y., Robinson, L. A., Ou, F., Roe, M. T., Ohman, E. M., Gibler, W. B., Smith, S. C., Peterson, E. D., & Becker, R. C. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.09.003 · Cited by 119
Platelets in Atherothrombosis
Vorchheimer, D. A., & Becker, R. C. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.1.59 · Cited by 119
On the influence of flow conditions and wettability on blood material interactions
Spijker, H. S., Graaff, R., Boonstra, P. W., Busscher, H. J., & van Oeveren, W. (2003) · Biomaterials · doi:10.1016/s0142-9612(03)00380-6 · Cited by 119
Prasugrel
Wiviott, S. D., Antman, E. M., & D, E. B. M. (2010) · Circulation · doi:10.1161/circulationaha.109.921502 · Cited by 119
Effectiveness of In-Laboratory High-Dose Clopidogrel Loading Versus Routine Pre-Load in Patients Undergoing Percutaneous Coronary Intervention
Sciascio, G. D., Patti, G., Pasceri, V., Gatto, L., Colonna, G., & Montinaro, A. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.067 · Cited by 118
Design of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial
Chimowitz, M. I., Lynn, M., Turan, T. N., Fiorella, D., Lane, B. F., Janis, S., & Derdeyn, C. P. (2011) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2011.05.001 · Cited by 118
Combination Antithrombotic Therapies
Gurbel, P. A., & Tantry, U. S. (2010) · Circulation · doi:10.1161/circulationaha.109.853085 · Cited by 121
Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs
Patti, G., Cavallari, I., Andreotti, F., Calabrò, P., Cirillo, P. L., Denas, G., Galli, M., Golia, E., Maddaloni, E., Marcucci, R., et al. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0080-2 · Cited by 122
Aspirin Resistance and Genetic Polymorphisms
Cambria-Kiely, J. A., & Gandhi, P. J. (2002) · Journal of Thrombosis and Thrombolysis · doi:10.1023/a:1022066305399 · Cited by 118
PAR4, but Not PAR1, Signals Human Platelet Aggregation via Ca2+ Mobilization and Synergistic P2Y12 Receptor Activation
Holinstat, M. A., Voss, B., Bilodeau, M. L., McLaughlin, J. N., Cleator, J. H., & Hamm, H. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602174200 · Cited by 118
Platelet Activation and Atherothrombosis
Kapoor, J. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmc080056 · Cited by 120
Antithrombotic Agents
Chan, N., & Weitz, J. I. (2019) · Circulation Research · doi:10.1161/circresaha.118.313155 · Cited by 120
Drug Insight: clopidogrel nonresponsiveness
Gurbel, P. A., & Tantry, U. S. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0602 · Cited by 117
effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial)
Bonz, A. W., Lengenfelder, B. D., Strotmann, J. M., Held, S., Turschner, O., Harre, K., Wacker, C. M., Waller, C., Kochsiek, N., Meesmann, M., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02014-4 · Cited by 117
Part 9: Acute Coronary Syndromes
O’Connor, R. E., Bossaert, L. L., Arntz, H.-R., Brooks, S. C., Diercks, D., Feitosa-Filho, G. S., Nolan, J. P., Hoek, T. L. V., Walters, D., Wong, A., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.985549 · Cited by 116
Usefulness of Platelet Response to Clopidogrel by Point-of-Care Testing to Predict Bleeding Outcomes in Patients Undergoing Percutaneous Coronary Intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study)
Patti, G., Pasceri, V., Vizzi, V., Ricottini, E., & Sciascio, G. D. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.11.025 · Cited by 116
Assessment of potential drug–drug interactions and its associated factors in the hospitalized cardiac patients
Murtaza, G., Khan, M. Y. G., Azhar, S., Khan, S. A., & Khan, T. M. (2015) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2015.03.009 · Cited by 115
Point-of-Care Whole Blood Impedance Aggregometry Versus Classical Light Transmission Aggregometry for Detecting Aspirin and Clopidogrel: The Results of a Pilot Study
Velik‐Salchner, C., Maier, S., Innerhofer, P., Streif, W., Klingler, A., Kolbitsch, C., & Fries, D. R. (2008) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31818524c1 · Cited by 116
Unstable Angina and Non–ST Elevation Myocardial Infarction
Braunwald, E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201109-1745ci · Cited by 115
Platelet Function Testing and Genotyping Improve Outcome in Patients Treated With Antithrombotic Agents
Gurbel, P. A., & Tantry, U. S. (2012) · Circulation · doi:10.1161/circulationaha.111.031195 · Cited by 115
Open issues in transcatheter aortic valve implantation. Part 2: procedural issues and outcomes after transcatheter aortic valve implantation
Bax, J. J., Delgado, V., Bapat, V., Baumgartner, H., Collet, J., Erbel, R., Hamm, C. W., Kappetein, A. P., Leipsic, J. A., Leon, M. B., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu257 · Cited by 114
2024 EACTS/EACTAIC Guidelines on patient blood management in adult cardiac surgery in collaboration with EBCP
Casselman, F. P. A., Lance, M. D., Ahmed, A. B., Ascari, A., Blanco-Morillo, J., Bolliger, D., Eid, M., Erdoes, G., Haumann, R. G., Jeppsson, A., et al. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae352 · Cited by 138
Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs
Pogue, J. M., Walter, S. D., & Yusuf, S. (2009) · Clinical Trials · doi:10.1177/1740774509105223 · Cited by 113
Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target
Gurbel, P. A., Antonino, M. J., Bliden, K. P., DiChiara, J., Suarez, T., Singla, A., & Tantry, U. S. (2008) · Platelets · doi:10.1080/09537100802351065 · Cited by 113
Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs
Steinhubl, S. R., Kastrati, A., & Berger, P. B. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.04.009 · Cited by 113
Duration of Dual Antiplatelet Therapy After Coronary Stenting
Montalescot, G., Brieger, D. B., Dalby, A. J., Park, S., & Mehran, R. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.053 · Cited by 112
Long-Term Outcomes by Clopidogrel Duration and Stent Type in a Diabetic Population With De Novo Coronary Artery Lesions
Brar, S. S., Kim, J., Brar, S. K., Zadegan, R., Ree, M. H., Liu, I.-L. A., Mansukhani, P. W., Aharonian, V. J., Hyett, R., & Shen, A. Y. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.01.063 · Cited by 112
Pancoronary plaque vulnerability in patients with acute coronary syndrome and ruptured culprit plaque: A 3-vessel optical coherence tomography study
Vergallo, R., Ren, X., Yonetsu, T., Kato, K., Uemura, S., Yu, B., Jia, H., Abtahian, F., Aguirre, A. D., Tian, J., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.10.011 · Cited by 118
ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention—summary article: A report of the American college of cardiology/American heart association task force on practice guidelines(ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention)
Smith, S., Feldman, T. E., Hirshfeld, J., Jacobs, A., Kern, M. J., King, S., Morrison, D. A., O'Neill, W. W., Schaff, H., Whitlow, P., et al. (2006) · Journal of the American College of Cardiology · doi:10.1002/ccd.20606 · Cited by 328
Clopidogrel and Bleeding After Coronary Artery Bypass Graft Surgery
Leong, J.-Y., Baker, R. A., Shah, P. J., Cherian, V. K., & Knight, J. L. (2005) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2005.03.074 · Cited by 112
Perioperative management of antiplatelet therapy
Oprea, A. D., & Popescu, W. M. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aet402 · Cited by 110
Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time
Wilhite, D. B., Comerota, A. J., Schmieder, F. A., Throm, R. C., Gaughan, J. P., & Rao, A. K. (2003) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(03)01029-2 · Cited by 111
Clopidogrel use and bleeding after coronary artery bypass graft surgery
Kim, J. H.-J., Newby, L. K., Clare, R. M., Shaw, L. K., Lodge, A. J., Smith, P. K., Jolicoeur, M. E., Rao, S. V., Becker, R. C., Mark, D. B., et al. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.06.034 · Cited by 111
Assessment of platelet inhibition secondary to clopidogrel and aspirin therapy in preoperative acute surgical patients measured by Thrombelastography® Platelet Mapping™
Collyer, T. C., Gray, D. P., Sandhu, R., Berridge, J., & Lyons, G. (2009) · British Journal of Anaesthesia · doi:10.1093/bja/aep039 · Cited by 111
Practical Management of Anticoagulation in Patients With Atrial Fibrillation
Kovacs, R. J., Flaker, G. C., Saxonhouse, S. J., Doherty, J. U., Birtcher, K. K., Cuker, A. C., Davidson, B. L., Giugliano, R. P., Granger, C. B., Jaffer, A. K., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.049 · Cited by 114
Effects of P2Y12 receptor antagonists beyond platelet inhibition – comparison of ticagrelor with thienopyridines
Nylander, S., & Schulz, R. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13429 · Cited by 110
STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management
Tibi, P. R., McClure, R. S., Huang, J., Baker, R. A., Fitzgerald, D., Mazer, C. D., Stone, M. E., Chu, D., Stammers, A. H., Dickinson, T., et al. (2021) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2021.03.011 · Cited by 113
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR
Escaned, J., Cao, D., Baber, U., Nicolas, J., Sartori, S., Zhang, Z., Dangas, G., Angiolillo, D. J., Briguori, C., Cohen, D. J., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab702 · Cited by 110
In-Hospital Patients Exposed to Clopidogrel Before Coronary Artery Bypass Graft Surgery: A Word of Caution
Ascione, R., Ghosh, A., Rogers, C. A., Cohen, A., Monk, C., & Angelini, G. D. (2005) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2004.09.046 · Cited by 110
Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin
Anand, S. S., Yusuf, S., Pogue, J. M., Ginsberg, J. S., & Hirsh, J. (2003) · Circulation · doi:10.1161/01.cir.0000077530.53367.e9 · Cited by 110
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial
Moukarbel, G. V., Signorovitch, J., Pfeffer, M., McMurray, J. J. V., White, H. D., Maggioni, A. P., Velazquez, E. J., Califf, R. M., Scheiman, J. M., & Solomon, S. D. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp256 · Cited by 110
Management of Antiplatelet Therapy in Patients With Coronary Artery Disease Requiring Cardiac and Noncardiac Surgery
Capodanno, D., & Angiolillo, D. J. (2013) · Circulation · doi:10.1161/circulationaha.113.003675 · Cited by 110
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial
Wiviott, S. D., White, H. D., Ohman, E. M., Fox, K. A. A., Armstrong, P. W., Prabhakaran, D., Hafley, G. E., Lokhnygina, Y. V., Boden, W. E., Hamm, C. W., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61451-8 · Cited by 111
Antithrombotic therapy for patients with STEMI undergoing primary PCI
Franchi, F., Rollini, F., & Angiolillo, D. J. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.18 · Cited by 110
Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome
Tarantini, G., Mojoli, M., Varbella, F., Caporale, R., Rigattieri, S., Andò, G., Cirillo, P. L., Pierini, S., Santarelli, A., Sganzerla, P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.053 · Cited by 113
Clopidogrel Pharmacogenomics and Risk of Inadequate Platelet Inhibition: US FDA Recommendations
Ellis, K., Stouffer, G. A., McLeod, H. L., & Lee, C. R. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.143 · Cited by 109
Efficacy Assessment of Meloxicam, a Preferential Cyclooxygenase-2 Inhibitor, in Acute Coronary Syndromes Without ST-Segment Elevation
Altman, R., Luciardi, H. L., Muntaner, J. A., Rio, F. D., Berman, S., López, R., & González, C. D. (2002) · Circulation · doi:10.1161/01.cir.0000021599.56755.a1 · Cited by 109
Safety and Exploratory Efficacy of the Novel Thrombin Receptor (PAR-1) Antagonist SCH530348 for Non-ST-Segment Elevation Acute Coronary Syndrome
Goto, S., Yamaguchi, T., Ikeda, Y., Kato, K., Yamaguchi, H., & Pk, J. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.3038 · Cited by 109
Signalling pathways and mechanisms of protection in pre‐ and postconditioning: historical perspective and lessons for the future
Cohen, M. V., & Downey, J. M. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12903 · Cited by 111
Optimal Timing of Intervention in Non–ST-Segment Elevation Acute Coronary Syndromes
Ryan, J. W., Peterson, E. D., Chen, A. Y., Roe, M. T., Ohman, E. M., Cannon, C. P., Berger, P. B., Saucedo, J. F., DeLong, E. R., Normand, S. T., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.582346 · Cited by 108
Acute ST-Segment Elevation Myocardial Infarction
Goodman, S. G., Menon, V., Cannon, C. P., Steg, P. G., Ohman, E. M., & Harrington, R. A. (2008) · CHEST Journal · doi:10.1378/chest.08-0665 · Cited by 107
Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy
Tanguay, J., Bell, A., Ackman, M. L., Bauer, R. D. C., Cartier, R., Chan, W., Douketis, J. D., Roussin, A., Schnell, G., Verma, S., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.07.001 · Cited by 105
Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis
Solo, K., Lavi, S., Kabali, C., Levine, G. N., Kulik, A., John‐Baptiste, A., Fremes, S. E., Martin, J. E., Eikelboom, J. W., Ruel, M., et al. (2019) · BMJ · doi:10.1136/bmj.l5476 · Cited by 108
Application of the TIMI Risk Score for Unstable Angina and Non-ST Elevation Acute Coronary Syndrome to an Unselected Emergency Department Chest Pain Population
Pollack, C. V., Sites, F. D., Shofer, F. S., Sease, K. L., & Hollander, J. E. (2006) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2006.tb00978.x · Cited by 107
Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE)
Budaj, A., Brieger, D. B., Steg, P. G., Goodman, S. G., Dabbous, O. H., Fox, K. A. A., Avezum, Á., Cannon, C. P., Mazurek, T., Flather, M. D., et al. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00509-x · Cited by 107
Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study
Sun, J. C. J., Teoh, K., Lamy, A. L., Sheth, T., Ellins, M. L., Jung, H. J., Yusuf, S., Anand, S. S., Connolly, S. J., Whitlock, R. P., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.07.035 · Cited by 107
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humans
Asai, F., Jakubowski, J. A., Naganuma, H., Brandt, J. T., Matsushima, N., Hirota, T., Freestone, S., & Winters, K. J. (2006) · Platelets · doi:10.1080/09537100600565551 · Cited by 107
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial
Bonaca, M. P., Bhatt, D. L., D, E. B. M., Cohen, M. C., Steg, P. G., Storey, R. F., Held, P. H., Jensen, E. C., & Sabatine, M. S. (2014) · American Heart Journal · doi:10.1016/j.ahj.2013.12.020 · Cited by 106
Coronary Artery Stents: II. Perioperative Considerations and Management
Newsome, L. T., Weller, R. S., Gerancher, J. C., Kutcher, M. A., & Royster, R. L. (2008) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181731e95 · Cited by 106
Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation
Weintraub, W. S., Mahoney, E. M., Lamy, A. L., Culler, S. D., Yuan, Y., Jaime, J., Gabriel, S., & Yusuf, S. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.11.051 · Cited by 106
Established treatments for acute ischaemic stroke
Khaja, A. M., & Grotta, J. C. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60154-8 · Cited by 106
P2Y 12 Antagonism
Michelson, A. D. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.160689 · Cited by 106

Authors: The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Affiliations: Hamilton General Hospital (CA)
Corresponding author: The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2001-08-16
Volume: 345
Issue: 7
Pages: 494-502
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa010746
OpenAlex: W1553345686
Cited by: 6,470
References: 16
Citations by year: 2026: 63 · 2025: 99 · 2024: 77 · 2023: 110 · 2022: 121 · 2021: 163 · 2020: 168 · 2019: 202 · 2018: 216 · 2017: 229 · 2016: 265 · 2015: 325 · 2014: 319 · 2013: 397 · 2012: 395
FWCI: 178.22
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords: clopidogrel, aspirin, antiplatelet therapy, major bleeding, refractory ischemia, cardiovascular mortality, myocardial infarction, stroke, heart failure, revascularization
MeSH terms: Clopidogrel, Acute Disease, Aged, Aspirin, Cardiovascular Diseases, Drug Therapy, Combination, Electrocardiography, Female, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Risk Factors, Ticlopidine, Myocardial Ischemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks